Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
A Novel Scoring System Proposal To Guide Surgical Treatment Indications For High Grade Gliomas In Elderly Patients: Dak-75.

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
A Novel Scoring System Proposal To Guide Surgical Treatment Indications For High Grade Gliomas In Elderly Patients: Dak-75.

Related Experiment Video

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

A novel scoring system proposal to guide surgical treatment indications for high grade gliomas in elderly patients: DAK-75.

Andrea Bianconi¹, Roberto Presta², Pietro La Cava³

¹Neurosurgery Unit, "Città Della Salute E Della Scienza" University Hospital, Department of Neuroscience "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10124, Turin, Italy. andrea.bianconi@edu.unito.it.

Neurosurgical Review

|October 25, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

A new DAK-75 score helps surgeons decide on high-grade glioma (HGG) resection for elderly patients. This score predicts 12-month mortality, aiding surgical decisions in patients aged 75 and older.

Keywords:

Elderly Glioblastoma Glioma Score

More Related Videos

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry

Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry

Published on: January 7, 2014

Related Experiment Videos

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells

Published on: March 28, 2021

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry

Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry

Published on: January 7, 2014

Area of Science:

Neurosurgery
Oncology
Geriatrics

Background:

High-grade gliomas (HGG) are the most common brain tumors in adults, with incidence increasing with age.
Selecting elderly patients (≥75 years) for surgical resection requires careful consideration of survival predictors.

Purpose of the Study:

To identify pre-surgical predictors of 12-month mortality in newly diagnosed HGG patients aged ≥75 years.
To develop a prognostic score to guide surgical decisions in this patient population.

Main Methods:

Retrospective observational single-center cohort study of 102 patients aged ≥75 years with newly diagnosed HGG.
Development of a multivariable logistic regression model using clinical, radiological, histological, and molecular data to predict 12-month overall survival.

Validation of the DAK-75 score, incorporating clinical presentation, tumor location, and Karnofsky Performance Status (KPS).

Main Results:

The DAK-75 score demonstrated good predictive performance (AUROC 0.822).
Higher DAK-75 scores correlated with higher 12-month mortality rates (92.2% vs 47.1%) and fewer surgical interventions.
Key predictors included clinical presentation, tumor location, and KPS.

Conclusions:

The DAK-75 score is a valuable tool for guiding neurosurgical decisions in elderly HGG patients.
The score aids in stratifying patients into low-risk and high-risk groups for 12-month mortality.
Further external and prospective validation of the DAK-75 score is warranted.